Undoubtedly, well-designed and adequately powered randomized controlled trials with the addition of an empagliflozin/metformin combination to insulin therapy are warranted in people with type 1 diabetes and a cardiovascular outcome trial that demonstrates these observations with respect to the reduction in major cardiovascular events. This evidence concerns the gene INS and type 1 diabetes mellitus.